Tag:

vaccines

Latest Headlines

Latest Headlines

Glaxo Ebola vax shows no adverse effects so far in first human trial

With the Ebola death toll mounting in West Africa, a Phase I trial of GlaxoSmithKline's experimental vaccine for the disease is underway at the U.S. National Institutes of Health.

Vaxxas' nanopatch garners WHO support in search of polio vax application

Australian nanopatch developer Vaxxas signed on with the World Health Organization this week in an effort to co-opt the company's patch for use with the polio vaccine. The WHO will help fund the research and move it through preclinical and clinical studies as the organization seeks to make polio a thing of the past.

USDA gives conditional approval for Zoetis PEDv vaccine

The U.S. Department of Agriculture has given conditional approval for use of Zoetis' vaccine to combat the porcine epidemic diarrhea virus, or PEDv, that has caused havoc in global swine herds, killing an estimated 8 million piglets in the U.S. alone since it was first reported more than a year ago.

Market research firm says needle-free vaccine delivery is the wave of the future

Expect more needle-free vaccines to come to market on the heels of the first approval of a needle-free delivery system for the inactivated flu vaccine, market research firm Frost & Sullivan says.

Pfizer, Merck, pick up hefty vax sales bump with CDC nod in seniors

Pfizer's Prevnar 13, the world's best-selling vaccine, scored a big win Wednesday, nabbing a CDC committee nod for universal use in adults over the age of 65. And once payer coverage kicks in, that's a nod that could be worth $2 billion for Pfizer, analysts say--with Merck's Pneumovax getting a boost, too.

A $635M win-win deal boosts Pfizer in vaccines, slims Baxter for spinoff

Looks like Pfizer's finally getting the vaccines expansion it's been hankering for. The company agreed to pick up Baxter's marketed vaccines portfolio for $635 million, building up its own business as the Illinois healthcare company slims down for a pharma unit spinoff next year.

Canada gives GSK 30 days to get its vaccine plant in order

GlaxoSmithKline is under pressure from not one, but two regulatory bodies to get problems under control at a flu vaccine plant in Canada. After the FDA handed the company a warning letter late last month, Health Canada now says the pharma giant has a month to lay out a plan for resolving issues there.

Experimental heart disease vaccine lowers arterial plaque in mice

Researchers at La Jolla Institute for Allergy and Immunology in California are spearheading an effort to develop the first vaccine for heart disease.

Pfizer, Novartis square off for tussle in meningitis vaccine market

Pfizer and Novartis have been racing to get their meningitis B vaccines to market for years. But as of Tuesday, the contest has never been closer, with both companies submitting approval applications to the FDA. Now, it's up to the agency to decide which shot gets the green light first--and first crack at the wide-open patient pool that comes with it.

Top 10 best-selling vaccines of 2013

The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top.